[Pharmacoeconomic model of the use of rifabutin in new cases of pulmonary tuberculosis].
The formalized procedures to commensurate the results and expenditures were used to make a comprehensive evaluation of the clinical efficiency and economical expediency of purposeful application of rifabutin in new cases of disseminated and destructive pulmonary tuberculosis.
Mednikov
B L
BL
Plaksin
D I
DI
Piiavskiĭ
S A
SA
D000904:Antibiotics, Antitubercular / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use*; D006801:Humans; D008962:Models, Theoretical; D012008:Recurrence; D017828:Rifabutin / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use*; D013997:Time Factors; D014397:Tuberculosis, Pulmonary / Q000145:classification / Q000188:drug therapy* / Q000191:economics* / Q000401:mortality
D000904:Antibiotics, Antitubercular; D017828:Rifabutin